Defining the role of panitumumab in colorectal cancer

Axel F Grothey

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Panitumumab is the first fully human anti-EGFR monoclonal antibody available for the treatment of advanced colorectal cancer. The drug appears to be well tolerated and has demonstrated antitumor activity and clinical benefit both as a single agent and in combination with cytotoxic chemotherapy.

Original languageEnglish (US)
JournalCommunity Oncology
Volume3
Issue number10 SUPPL. 4
StatePublished - Oct 2006

Fingerprint

Colorectal Neoplasms
Monoclonal Antibodies
Drug Therapy
Pharmaceutical Preparations
Therapeutics
panitumumab

ASJC Scopus subject areas

  • Oncology

Cite this

Defining the role of panitumumab in colorectal cancer. / Grothey, Axel F.

In: Community Oncology, Vol. 3, No. 10 SUPPL. 4, 10.2006.

Research output: Contribution to journalArticle

Grothey, AF 2006, 'Defining the role of panitumumab in colorectal cancer', Community Oncology, vol. 3, no. 10 SUPPL. 4.
Grothey, Axel F. / Defining the role of panitumumab in colorectal cancer. In: Community Oncology. 2006 ; Vol. 3, No. 10 SUPPL. 4.
@article{a1d40595fd9046adb6973713b2f9554e,
title = "Defining the role of panitumumab in colorectal cancer",
abstract = "Panitumumab is the first fully human anti-EGFR monoclonal antibody available for the treatment of advanced colorectal cancer. The drug appears to be well tolerated and has demonstrated antitumor activity and clinical benefit both as a single agent and in combination with cytotoxic chemotherapy.",
author = "Grothey, {Axel F}",
year = "2006",
month = "10",
language = "English (US)",
volume = "3",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "10 SUPPL. 4",

}

TY - JOUR

T1 - Defining the role of panitumumab in colorectal cancer

AU - Grothey, Axel F

PY - 2006/10

Y1 - 2006/10

N2 - Panitumumab is the first fully human anti-EGFR monoclonal antibody available for the treatment of advanced colorectal cancer. The drug appears to be well tolerated and has demonstrated antitumor activity and clinical benefit both as a single agent and in combination with cytotoxic chemotherapy.

AB - Panitumumab is the first fully human anti-EGFR monoclonal antibody available for the treatment of advanced colorectal cancer. The drug appears to be well tolerated and has demonstrated antitumor activity and clinical benefit both as a single agent and in combination with cytotoxic chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=33845605751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845605751&partnerID=8YFLogxK

M3 - Article

VL - 3

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 10 SUPPL. 4

ER -